Chemopreventive efficacy of inositol Hexaphosphate against prostate tumor growth and progression in tramp mice

Clinical Cancer Research

Volumn 14, Issue 10, 2008, Pages 3177-3184

  Raina, Komal ^a   Rajamanickam, Subapriya ^a   Singh, Rana P ^a,c   Agarwal, Rajesh ^a,b,d  

^a School of Pharmacy

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c JAWAHARLAL NEHRU UNIVERSITY   (India)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHYTIC ACID; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; ADENOCARCINOMA; ANIMAL; DRUG EFFECT; PROSTATE TUMOR; TRANSGENIC MOUSE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, TRANSGENIC; PHYTIC ACID; PROSTATIC NEOPLASMS;

EID: 49649098564     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5275     Document Type: Article

References (44)

1. Shamsuddin AM, Vucenik I, Cole KE. IP6: a novel anti-cancer agent. Life Sci 1997:61:343-54.
2. Vucenik I, Shamsuddin AM. Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic. J Nutr 2003;133:3778-84S.
3. Singh RP, Agarwal R. Prostate cancer and inositol hexaphosphate: efficacy and mechanisms. Anticancer Res 2005;25:2891 -903.
4. Graf E, Eaton JW. Antioxidant functions of phytic acid. Free Radic Biol Med 1990:8:61 -9.
5. Jariwalla RJ. Rice-bran products: phytonutrients with potential applications in preventive and clinical medicine. Drugs Exp Clin Res 2001;27:17-26.
6. Fox CH, Eberl M. Phytic acid (IP6), novel broad spectrum anti-neoplastic agent: a systematic review. Complement Ther Med 2002;10:229-34.
7. Shamsuddin AM, Vucenik I. Mammary tumor inhibition by IP6: a review. Anticancer Res 1999; 19: 3671-4.
8. Saied IT, Shamsuddin AM. Up-regulation of the tumor suppressor gene p53 and WAF1 gene expression by IP6 in HT-29 human colon carcinoma cell line. Anticancer Res 1998:18:1479-84.
9. Shamsuddin AM, Yang GY. Inositol hexaphosphate inhibits growth and induces differentiation of PC-3 human prostate cancer cells. Carcinogenesis 1995; 16:1975-9.
10. 1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. Carcinogenesis 2003:24: 555-63.
11. Vucenik I, Tantivejkul K, Zhang ZS, Cole KE, Saied I, Shamsuddin AM. IP6 in treatment of liver cancer. I. IP6 inhibits growth and reverses transformed phenotype in HepG2 human liver cancer cell line. Anticancer Res 1998:18:4083-90.
12. Vucenik I, Kalebic T, Tantivejkul K, Shamsuddin AM. Novel anticancer function of inositol hexaphosphate: inhibition of human rhabdomyosarcoma in vitro and in vivo. Anticancer Res 1998:18:1377-84.
13. Shamsuddin AM, Baten A, Lalwani ND. Effects of inositol hexaphosphate on growth and differentiation in K-562 erythroleukemia cell line. Cancer Lett 1992; 64:195-202.
14. Huang C, Ma WY, Hecht SS, Dong Z. Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3′ kinase. Cancer Res 1997;57:2873-8.
15. Shamsuddin AM, Elsayed AM, Ullah A. Suppression of large intestinal cancer in F344 rats by inositol hexaphosphate. Carcinogenesis 1988:9:577 - 80.
16. Shamsuddin AM, Ullah A. Inositol hexaphosphate inhibits large intestinal cancer in F344 rats 5 months after induction by azoxymethane. Carcinogenesis 1989;10:625-6.
17. Shamsuddin AM, Ullah A, Chakravarthy AK. Inositol and inositol hexaphosphate suppress cell proliferation and tumor formation in CD-1 mice. Carcinogenesis 1989;10:1461-3.
18. Ishikawa T, Nakatsuru Y, Zarkovic M, Shamsuddin AM. Inhibition of skin cancer by IP6 in vivo: initiation-promotion model. Anticancer Res1999;19:3749-52.
19. Vucenik I, Zhang ZS, Shamsuddin AM. IP6 in treatment of liver cancer. II. Intra-tumoral injection of IP6 regresses pre-existing human liver cancer xenotrans-planted in nude mice. Anticancer Res 1998:18: 4091 -6.
20. Wattenberg LW. Chemoprevention of pulmonary carcinogenesis by myo-inositol. Anticancer Res 1999; 19:3659-61.
21. Vucenik I, Tomazic VJ. Fabian D, Shamsuddin AM. Antitumor activity of phytic acid (inositol hexaphosphate) in murine transplanted and metastatic fibrosarcoma, a pilot study. Cancer Lett 1992;65:9-13.
22. Jenab M.Thompson LU. Purified and endogenous phytic acid in wheat bran affects early biomarkers of colon cancer risk. IARC Sci Publ 2002;156:387-9.
23. 1 arrest and apoptotic death of androgen-dependent human prostate carcinoma LNCaP cells. Neoplasia 2004;6:646-59.
24. Zi X, Singh RP, Agarwal R. Impairmen of erbB1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells. Carcinogenesis 2000;21:2225-35.
25. Agarwal C, Dhanalakshmi S, Singh RP, Agarwal R. Inositol hexaphosphate inhibits constitutive activation of NF-κB in androgen-independent human prostate carcinoma DU145 cells. Anticancer Res 2003:23: 3855-61.
26. Sharma G, Singh RP, Agarwal R. Growth inhibitory and apoptotic effects of inositol hexaphosphate in transgenic adenocarcinoma of mouse prostate (TRAMP-C1) cells. Int J Oncol 2003;23:1413-8.
27. Singh RP, Sharma G, Mallikarjuna GU, Dhanalakshmi S, Agarwal C, Agarwal R. In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factor. Clin Cancer Res 2004;10. 244-50.
28. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse Proc Natl Acad Sci USA 1995;92:3439-43.
29. Greenberg NM, DeMayo FJ, Sheppard PC, et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 1994;8:230-9.
30. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM. Pathologic progression of autochthonous prostate cancer in theTRAMP model Prostate Cancer Prostatic Dis1999;2:70-5.
31. Gingrich JR, Greenberg NM. A transgenic mouse prostate cancer model. Toxicol Pathol 1996:24:502-4.
32. Singh RP, Sharma G. Dhanalakshmi S. Agarwal C. Agarwal R. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev 2003;12:933-9.
33. Raina K, Singh RP, Agarwal R, Agarwal C. Oral grape seed extract inhibits prostate tumor growth and progression in TRAMP mice. Cancer Res 2007; 67:5976-82.
34. Raina K, Blouin MJ, Singh RP, et al. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2007;67:11083-91.
35. Stewart AB, Lwaleed BA, Douglas DA, Birch BR Current drug therapy for prostate cancer, an overview. Curr Med Chem Anticancer Agents 2005:5 603-12.
36. Clinton SK, Giovannucci E, Diet, nutrition, and prostate cancer. Annu Rev Nutr 1998:18:413-40
37. Boyle P, Seven G, Giles GG. The epidemiology of prostate cancer. Urol Clin North Am 2003,30 209 17
38. Abdulla M, Gruber P. Role of diet modification in cancer prevention. Biofactors 2000:12:45 51.
39. Bidoli E. Talamini R, Bosetti C. et al. Macronutnents fatty acids, cholesterol and prostate cancer risk Ann Oncol 2005;16:152-7.
40. Klein EA. Cnemoprevention of prostate cancer Annu Rev Med 2006:57 49-63.
41. Singh RP, Agarwal R. Mechanisms of action of novel agents for prostate cancer cnemoprevention Endocr Relat Cancer 2006:13:751 -78
42. Vucenik I, Shamsuddin AM. Protection against cancer by dietary IP6 and inositol. Nutr Cancer 2006:55 109-25.
43. Klein S, McCormick F. Levitzki A. Killing time for cancer cells. Nat Rev Cancer 2005:5:573-80
44. Agarwal R Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents Biochem Pharmacol 2000:60:1051-9